drugset / Trial / NCT01840592
Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib
Phase 2
Active not recruiting
30 enrolled
Memorial Sloan Kettering Cancer Center
Bayer · collabNational Comprehensive Cancer Network · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to find out what effects, good and/or bad, the combination of the drug sorafenib in combination with the drug doxorubicin might have on the growth and spread of liver cancer (HCC).
Timeline
- Start
- 2013-04
- Primary completion
- 2027-04
- Completion
- 2027-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Doxorubicin | Other / unclassified | 60 mg/m2 | Intravenous |
| Subject | Sorafenib | Small molecule | 400 mg | Oral |